Beranda › PPOK › Tennessee › Knoxville
Uji klinis PPOK di Knoxville, TN
5 studi untuk PPOK mencari peserta di lokasi sekitar Knoxville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
Menerima peserta
- Fort Sanders Regional Medical Center (StatCare), Knoxville
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Menerima pesertaFase 3
- Research Site, Knoxville
Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
Menerima pesertaFase 4
- The University of Tennessee Graduate School of Medicine, Knoxville
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Menerima pesertaFase 3
- GSK Investigational Site, Knoxville
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Menerima pesertaFase 3
- GSK Investigational Site, Knoxville
Uji klinis PPOK di kota lain
- Philadelphia, PA23 studi
- Miami, FL18 studi
- Birmingham, AL17 studi
- Boston, MA17 studi
- Houston, TX15 studi
- Orlando, FL15 studi
- Baltimore, MD14 studi
- Chicago, IL14 studi
- Dallas, TX12 studi
- Pittsburgh, PA12 studi
- New York City, NY11 studi
- Ann Arbor, MI10 studi
Studi lain di Knoxville
- Kanker Paru Non-Sel Kecil14 studi
- Kanker Paru10 studi
- Obesitas10 studi
- Kanker Payudara9 studi
- Kanker (semua jenis)8 studi
- Gagal Jantung7 studi
- Kanker Metastatik7 studi
- Kelebihan Berat Badan7 studi
- Penyakit Kardiovaskular6 studi
- Tekanan Darah Tinggi5 studi
- Melanoma5 studi
- Diabetes Tipe 25 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.